Switching From TDF-based Antiretroviral Therapy Regimens to B/F/TAF in Virally Suppressed Adults With HIV-1 Infection

Phase 4 Unknown 150 enrolled Shanghai Public Health Clinical Center Xixi Hospital of Hangzhou · collab Yunnan AIDS Care Center · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the safety and efficacy of bictegravir/emtricitabine/tenofovir alafenamide versus tenofovir disoproxil fumarate-based antiretroviral regimens in HIV-infected individuals with virological suppression.

Timeline

Start: 2021-12-08
Primary completion: 2024-02-28
Completion: 2024-04-28

Publications

Shao Y, Yang X, Yu J, Wang X, Wang J, Liu M, Yang Z, Han J, Zhang R, Liu L, Shen Y, Sun M, Wu L, Zheng Z, Tang Y, Yang J, Wang Z, Qi T, Xu S, Xun J, Sun J, Song W, Chen J. Bone Mineral Density Changes in People with HIV Who had Immediate Switch Versus Deferred Switch from Tenofovir Disoproxil Fumarate-Based Regimens to Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Multicenter, Open-Label, Randomized Clinical Trial. Infect Dis Ther. 2026 Jan;15(1):165-181. doi: 10.1007/s40121-025-01262-8. Epub 2025 Nov 21.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bictegravir/emtricitabine/tenofovir alafenamide	Unknown	—	—
Comparator	Bictegravir/emtricitabine/tenofovir alafenamide	Unknown	—	—
Comparator	Tenofovir disoproxil fumarate	Small molecule	—	—

Switching From TDF-based Antiretroviral Therapy Regimens to B/F/TAF in Virally Suppressed Adults With HIV-1 Infection

Summary

Timeline

Publications

Drugs

Indications